Literature DB >> 15616412

Comparison of cardiovascular risk factors and drug use in 14,544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease.

Vanina Bongard1, Jean-Pierre Cambou, Alain Lezorovcz, Jean Ferrères, Alec Vahanan, Gérard Jullen, Gérard Coppe, Martine Guerllot, Marie-Annick Herrmann, Jean-Louis Mas.   

Abstract

BACKGROUND: Atherothrombosis is a systemic disease affecting coronary, cerebral, and lower limb arteries, and requiring secondary prevention measures.
DESIGN: Data from three observational studies carried out in 1999-2000 (ECLAT1, APRES, PRISMA) were pooled to describe the prevalence of cardiovascular risk factors and the patterns of drug use in atherothrombotic patients.
METHODS: General practitioners and cardiologists engaged in a private practice and evenly distributed in France recruited consecutive patients who had a history of at least one atherothrombotic event: myocardial infarction (MI), ischaemic stroke, and/or peripheral arterial disease (PAD).
RESULTS: The sample was composed of 14 544 patients (men: 75.0%, age 75 or older: 31.0%). At least one of the four major risk factors (smoking, hypertension, hypercholesterolaemia, diabetes) was present in 94.3% of the sample. Prevalence of drug use was: 78.8% (antiplatelet agents), 48.5% (statins), 36.7% (beta-blockers), and 33.4% [angiotensin-converting enzyme (ACE) inhibitors]. After adjustment for confounders, statins were taken in a significantly larger extent in patients with a history of isolated MI than in those with a previous ischaemic stroke or PAD, or in patients who suffered from both MI and ischaemic stroke. Isolated MI (as compared with ischaemic stroke and PAD) was significantly and independently associated with a higher probability to take antiplatelet agents, beta-blockers or ACE inhibitors.
CONCLUSIONS: At least one conventional risk factor was observed in almost all atherothrombotic patients. Use of preventive drugs was lower in patients with a history of ischaemic stroke or PAD, and should increase, accordingly to the results of recent randomized controlled trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15616412     DOI: 10.1097/00149831-200410000-00006

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  5 in total

1.  Mortality after myocardial infarction: impact of gender and smoking status.

Authors:  Morten Grundtvig; Terje P Hagen; Elin S Amrud; Aasmund Reikvam
Journal:  Eur J Epidemiol       Date:  2011-02-19       Impact factor: 8.082

2.  Management and in-hospital outcome of patients with first episode of acute myocardial infarction: impact of diabetes mellitus.

Authors:  Aysegul Atmaca; Serkan Dogan; Selcuk Dagdelen; Giray Kabakci; Sirri Kes; Nasih Nazli; Tomris Erbas
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

3.  Targeted screening for peripheral arterial disease in general practice: a pilot study in a high risk group.

Authors:  Neil C Campbell; Caroline McNiff; Jane Sheran; Julie Brittenden; Amanda J Lee; Lewis D Ritchie
Journal:  Br J Gen Pract       Date:  2007-04       Impact factor: 5.386

4.  Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort.

Authors:  Uwe Zeymer; Klaus G Parhofer; David Pittrow; Christiane Binz; Markus Schwertfeger; Tobias Limbourg; Joachim Röther
Journal:  Clin Res Cardiol       Date:  2009-02-16       Impact factor: 5.460

5.  Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.

Authors:  Saskia H Meves; Thomas Hummel; Heinz G Endres; Nora Mayböck; Andreas F C Kaiser; Kay D Schröder; Katja Rüdiger; Ursula Overbeck; Achim Mumme; Andreas Mügge; Horst Neubauer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.